[go: up one dir, main page]

MX2018001722A - Derivados del acido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridi n-3-il acetico como inhibidores de la replicacion del virus de la inmunodeficiencia humana. - Google Patents

Derivados del acido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridi n-3-il acetico como inhibidores de la replicacion del virus de la inmunodeficiencia humana.

Info

Publication number
MX2018001722A
MX2018001722A MX2018001722A MX2018001722A MX2018001722A MX 2018001722 A MX2018001722 A MX 2018001722A MX 2018001722 A MX2018001722 A MX 2018001722A MX 2018001722 A MX2018001722 A MX 2018001722A MX 2018001722 A MX2018001722 A MX 2018001722A
Authority
MX
Mexico
Prior art keywords
alkyl
alkoxy
compounds
tetrahydroisoquinolin
pyridin
Prior art date
Application number
MX2018001722A
Other languages
English (en)
Inventor
F Kadow John
Narasimhulu Naidu B
Wang Tao
J Eastman Kyle
E Parcella Kyle
Yin Zhiwei
Zhang Zhongxing
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56851651&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018001722(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of MX2018001722A publication Critical patent/MX2018001722A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulgan compuestos de Fórmula I, incluyendo sales farmacéuticamente aceptables, composiciones farmacéuticas que comprenden los compuestos, procedimientos de preparación de los compuestos y su uso en la inhibición de la integrasa del VIH y tratamiento de infectados con el VIH o SIDA. En los compuestos de la fórmula (I); R1 está seleccionado de hidrógeno, alquilo o cicloalquilo; R2 está seleccionado de tetrahidroisoquinolinilo y está sustituido con 1 sustituyente R6 y también con 0-3 sustituyentes halo o alquilo; R3 está seleccionado de azetidinilo, pirrolidinilo, piperidinilo, piperazinilo, morfolinilo, homopiperidinilo, homopiperazinilo u homomorfolinilo, y está sustituido con 0-3 sustituyentes seleccionados de ciano, halo, alquilo, haloalquilo, alcoxi y haloalcoxi; R4 está seleccionado de alquilo o haloalquilo; R5 es alquilo; R6 está seleccionado de Ar1, (Ar1)alquilo, (cromanil)alquilo, cianocicloalquilo o (dihidrobenzodioxinil)alqui lo; y Ar1 es fenilo sustituido con 0-5 sustituyentes seleccionados de ciano, halo, alquilo, cicloalquilo, haloalquilo, hidroxi, alcoxi, haloalcoxi, (hidroxi)alcoxi, (alcoxi)alcoxi, fenoxi, benciloxi, carboxi, fenilo y cianocicloalquilo. (ver Fórmula).
MX2018001722A 2015-08-11 2016-08-10 Derivados del acido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridi n-3-il acetico como inhibidores de la replicacion del virus de la inmunodeficiencia humana. MX2018001722A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562203791P 2015-08-11 2015-08-11
PCT/IB2016/054832 WO2017025917A1 (en) 2015-08-11 2016-08-10 5-(n-benzyl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Publications (1)

Publication Number Publication Date
MX2018001722A true MX2018001722A (es) 2018-05-16

Family

ID=56851651

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001722A MX2018001722A (es) 2015-08-11 2016-08-10 Derivados del acido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridi n-3-il acetico como inhibidores de la replicacion del virus de la inmunodeficiencia humana.

Country Status (23)

Country Link
US (2) US10189816B2 (es)
EP (1) EP3334716A1 (es)
JP (1) JP6782766B2 (es)
KR (1) KR20180032649A (es)
CN (1) CN108137534A (es)
AR (1) AR105653A1 (es)
AU (1) AU2016306089B2 (es)
CA (1) CA2994791A1 (es)
CL (1) CL2018000363A1 (es)
CO (1) CO2018001359A2 (es)
CR (1) CR20180091A (es)
DO (1) DOP2018000035A (es)
EA (1) EA033057B1 (es)
HK (1) HK1249503A1 (es)
IL (1) IL257240B (es)
MA (1) MA42614A (es)
MX (1) MX2018001722A (es)
PE (1) PE20181002A1 (es)
PH (1) PH12018500294A1 (es)
TW (1) TWI657086B (es)
UA (1) UA120464C2 (es)
WO (1) WO2017025917A1 (es)
ZA (1) ZA201800689B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3334723B1 (en) * 2015-08-12 2019-09-18 VIIV Healthcare UK (No.5) Limited 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
TW201718537A (zh) * 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
EP3455217A1 (en) * 2016-05-11 2019-03-20 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US10407410B2 (en) 2016-05-11 2019-09-10 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US20190152957A1 (en) * 2016-05-11 2019-05-23 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US20200016136A1 (en) * 2017-01-03 2020-01-16 Viiv Healthcare Uk (No. 5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2018127800A1 (en) * 2017-01-03 2018-07-12 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939545B2 (en) * 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
JP5269086B2 (ja) * 2007-11-15 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスの複製阻害薬
WO2009062288A1 (en) 2007-11-15 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
WO2009062308A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
BRPI0820307A2 (pt) 2007-11-16 2019-09-24 Boehringer Ingelheim Int inibidores de replicação do vírus da imunodeficiência humana
US8338441B2 (en) * 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
KR101483834B1 (ko) 2009-12-23 2015-01-16 카트호리이케 유니버시타이트 로이펜 항바이러스 화합물
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
CN105189511B (zh) 2013-03-13 2017-05-24 百时美施贵宝公司 人免疫缺陷病毒复制的抑制剂
ES2623904T3 (es) 2013-03-14 2017-07-12 VIIV Healthcare UK (No.5) Limited Inhibidores de la replicación del virus de la inmunodeficiencia humana
US9193720B2 (en) * 2014-02-20 2015-11-24 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
PT3116880T (pt) * 2014-02-20 2018-05-10 Viiv Healthcare Uk No 5 Ltd Macrociclos de ácido piridin-3-il acético como inibidores da replicação do vírus da imunodeficiência humana
EP3334723B1 (en) * 2015-08-12 2019-09-18 VIIV Healthcare UK (No.5) Limited 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
TW201718537A (zh) * 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
US10214516B2 (en) * 2015-08-12 2019-02-26 VIIV Healthcare UK (No.5) Limited 5-(N-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
DOP2018000035A (es) 2018-03-30
JP2018522927A (ja) 2018-08-16
IL257240B (en) 2020-02-27
ZA201800689B (en) 2021-08-25
UA120464C2 (uk) 2019-12-10
CR20180091A (es) 2018-06-13
AU2016306089A1 (en) 2018-03-01
CN108137534A (zh) 2018-06-08
EP3334716A1 (en) 2018-06-20
PE20181002A1 (es) 2018-06-26
TW201718549A (zh) 2017-06-01
HK1249503A1 (zh) 2018-11-02
MA42614A (fr) 2021-05-26
EA033057B1 (ru) 2019-08-30
CO2018001359A2 (es) 2018-05-10
IL257240A (en) 2018-03-29
US10189816B2 (en) 2019-01-29
CA2994791A1 (en) 2017-02-16
EA201890361A1 (ru) 2018-11-30
AU2016306089B2 (en) 2018-08-09
US20180230129A1 (en) 2018-08-16
JP6782766B2 (ja) 2020-11-11
WO2017025917A1 (en) 2017-02-16
TWI657086B (zh) 2019-04-21
KR20180032649A (ko) 2018-03-30
US20190092754A1 (en) 2019-03-28
AR105653A1 (es) 2017-10-25
PH12018500294A1 (en) 2018-08-13
CL2018000363A1 (es) 2018-07-06

Similar Documents

Publication Publication Date Title
PH12018500294A1 (en) 5-(n-benzyl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
ZA202500997B (en) Benzoxazepin oxazolidinone compounds and methods of use
TN2017000535A1 (en) Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
GEAP202215134A (en) Heterocyclic compounds as immunomodulators
PH12012500752A1 (en) Benzimidazole-imidazole derivatives
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
SG10201805033XA (en) Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MY174042A (en) Fused bicyclic sulfamoyl derivative and the use thereof as medicaments for the treatment of hepatitis b.
MX2015014033A (es) Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
PH12016500723B1 (en) Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
TW200833675A (en) Nicotinamide derivatives
PH12016500553B1 (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MX2015011229A (es) Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b.
AR099511A1 (es) Derivados del ácido piridin-3-ilacético como inhibidores de la replicación del virus de inmunodeficiencia humana
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2018008095A (es) Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
TN2019000170A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
MY203207A (en) 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
AU2012360910A8 (en) Quinazolinone derivatives as HCV inhibitors
MX2018014165A (es) Compuestos heterociclicos utiles como agentes antibacterianos y metodo de produccion.